Trials / Completed
CompletedNCT06800157
Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of LW402 Tablets in Patients With Moderate to Severe Active Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This Phase IIa study is designed to evaluate the dose-response relationship, efficacy, safety, and tolerability of LW402 tablets administered for 12 weeks in adult patients with active rheumatoid arthritis receiving background methotrexate (MTX) therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Drug: LW402 | Oral tablets administered BID |
| DRUG | Other: placebo | Placebo to match LW402 administered BID |
| DRUG | MTX | Background treatment with MTX once a week |
Timeline
- Start date
- 2023-02-27
- Primary completion
- 2024-05-26
- Completion
- 2024-08-30
- First posted
- 2025-01-29
- Last updated
- 2025-10-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06800157. Inclusion in this directory is not an endorsement.